Company intelligence / Profile preview

Lifera Omics

Riyadh, Riyadh Province, Saudi Arabia

Ownership: Private
Development stage: Other

Overview

Lifera Omics, a subsidiary of Lifera established in January 2024, is focused on developing at-scale, state-of-the-art genomic and multiomic testing capabilities in Saudi Arabia. The company operates as a joint venture with CENTOGENE, leveraging the latter’s global expertise and expansive biodatabase to deliver high-throughput genetic, transcriptomic, and other omic diagnostic services for clinical, population health, and R&D applications. The platform aims to accelerate precision medicine for rare and common diseases in the Gulf region, supported by a significant investment and international partnership[3][4].

Therapeutic areas: NeurologyRare Diseases
Modalities: NGS-based diagnosticsMultiomic profilingGenetic testing
Industry: Molecular Diagnostics

Partnerships

CENTOGENE (Lifera/CENTOGENE joint venture)

Beyond the preview

Go deeper on Lifera Omics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lifera Omics.

Explore the full profile